Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 1999, for Aastrom Biosciences, Inc. (Note: The input metadata referenced "Vericel Corp," but the filing text explicitly identifies the registrant as Aastrom Biosciences, Inc.). Aastrom is a development-stage biotechnology company focused on the ex vivo production of human cells for cell and gene therapy. The company's primary product candidate is the AastromReplicell System. Due to funding limitations, the company suspended European marketing activities and significantly reduced U.S. clinical trial programs in late 1999 to pursue strategic alternatives, including a potential merger or acquisition.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 1999 | Six Months Ended Dec 31, 1998 | As of Dec 31, 1999 |
|---|---|---|---|
| Total Revenues | $789,000 | $370,000 | - |
| Net Loss | $(5,661,000) | $(5,638,000) | - |
| Net Loss Per Share (Basic/Diluted) | $(0.34) | $(0.42) | - |
| Cash and Cash Equivalents | - | - | $3,550,000 |
| Total Assets | - | - | $4,433,000 |
| Total Liabilities | - | - | $1,559,000 |
| Accumulated Deficit | - | - | $(76,183,000) |
| Net Cash Used in Operating Activities | $(3,870,000) | $(5,057,000) | - |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues for the six months ended December 31, 1999, increased to $789,000 from $370,000 in the prior year period. This increase was driven by grant revenues ($620,000 vs. $370,000) and the introduction of product sales and rentals ($169,000 vs. $0).
- Expense Reduction: Total costs and expenses decreased to $6,589,000 from $7,605,000. Research and development expenses dropped significantly to $3,479,000 from $6,258,000, reflecting the suspension of European marketing and reduced clinical activities.
- Inventory Write-down: Cost of product sales and rentals for the six months ended December 31, 1999, was $1,251,000, primarily consisting of a write-down of AastromReplicell System inventory following the suspension of marketing activities.
- Cash Position: Cash and cash equivalents decreased by $3,978,000 to $3,550,000, driven by $3,870,000 in operating cash usage and $127,000 in capital equipment purchases.
Outlook, Risks, and Management Commentary
- Liquidity Risk: Management states that if additional funding is not obtained on a timely basis, the company likely will not be able to continue operations through June 30, 2000.
- Strategic Shift: The company has suspended European marketing and reduced U.S. clinical trials to focus on corporate strategic alternatives, such as mergers or acquisitions, to secure operating capital.
- Future Funding: The company expects to incur net operating losses until significant product sales commence. Future capital requirements depend on the success of strategic partnering discussions and the ability to raise funds through public or private financing.
- Regulatory and Clinical Risks: Commercialization is contingent upon FDA approval and successful clinical trials. The company faces uncertainties regarding patient accrual, trial results, and regulatory compliance (CE Mark in Europe).
- Stock Listing: The company faced potential delisting from Nasdaq due to stock price falling below $1.00 but regained compliance in February 2000.
- Subsequent Events: In January 2000, the company received $483,000 from warrant exercises and a convertible loan to finance operations during strategic discussions.
Investor Verification Checklist
- Verify the company's ability to secure additional funding before June 30, 2000, to avoid cessation of operations.
- Monitor progress of strategic partnership or merger discussions as the primary path to capital.
- Review the status of the AastromReplicell System's regulatory approvals (FDA and CE Mark) and clinical trial resumption plans.
- Assess the impact of the inventory write-down ($1.25M) on future cost structures if marketing resumes.
- Confirm the company's continued compliance with Nasdaq listing requirements.